ClinicalTrials.gg
RecruitingNCT02844049EQOLOCUpdated Nov 29, 2023

European Study of Quality of Life in Resistant OCD Patients Treated by STN DBS

An interventional study of Deep Brain Stimulation in Obsessive-Compulsive Disorder, sponsored by University Hospital, Grenoble. Recruiting at 8 sites in 4 countries. Open to participants aged 18 Years to 69 Years. Per ClinicalTrials.gov, last updated 2023-11-29.

Sponsored by University Hospital, Grenoble · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Jul 2026, 4 months ago, but the record still lists the study as recruiting.
  • Started Sep 2016; still recruiting 10 years 2 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
60
Allocation
Randomized
Ages
18 Years to 69 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 20 studies in Obsessive-Compulsive Disorder with a site in France — 5 open to participants now, 6 under way, none of them phase 3. Obsessive-Compulsive Disorder · France.

Planned enrollment
6th of 18
60 · median 45
Started
2016
with 2 others
No phase
14 of 20
5 open now
Registered
9th of 20
by date
Lead sponsor
3 of 20
University Hospital, Grenoble

Among the 20 studies in Obsessive-Compulsive Disorder with a site in France, this one is the 6th largest by planned enrollment of the 18 interventional ones that give a count, is one of 3 that started in 2016, is one of 14 with no phase, and was the 9th registered.

Obsessive-Compulsive Disorder

637 studies on the registry are indexed under Obsessive-Compulsive Disorder; 167 are open to participants now.

Browse Obsessive-Compulsive Disorder studies →

Open to participants now

5 of the 20 studies in Obsessive-Compulsive Disorder with a site in France are open now. Recruiting first, the newest first:

All 5 open studies →

A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →

Who these studies take

Of the 120 Obsessive-Compulsive Disorder studies recruiting now, 30 (25%) set no upper age limit and 82 (68%) stop at 75 or younger; 28 take children under 18; 19 take healthy volunteers.

This study: 18 Years to 69 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 20 studies in Obsessive-Compulsive Disorder with a site in France, or all of them as a file.
02

Study summary

Obsessive-Compulsive Disorder (OCD) is among the most disabling psychiatric disorders as more than 40% of patients are resistant to the standard pharmacological and psychotherapy approaches and about 10% show severe disability and require institutionalization. These resistant patients may benefit from new surgical therapeutic approaches such as Deep Brain Stimulation (DBS) using high frequency stimulation of specific cerebral regions to modulate neural networks. Although promising, these results need nevertheless to be replicated and confirmed within a larger cohort of patients and considering a different main objective, instead of clinical improvement only. Indeed, despite a positive treatment response, adaptive functioning and quality of life may continue to be negatively impacted in OCD. Thus beyond symptom reduction, health-related quality of life (QoL) represents a more important objective of a treatment, as it includes both the individual's functional status and the individual's subjective perception of the impact of the illness on the patient's life. STN DBS induces significant clinical improvement, which may not be proportional to the QoL gain. Consequently, QoL appears to be a better outcome to target in the coming studies than clinical improvement alone. THe investigators thus propose a prospective study assessing the QoL changes of resistant OCD patients under STN DBS+BMT versus Best Medical Treatment (BMT) at 12 months, in order to assess the DBS induced gain in QoL in BMT-managed patients versus BMT alone.

Read the detailed description

The study will focus on an innovative therapeutic strategy (DBS) and on an original objective, quality of life, which is considered to better reflect the impact of a therapeutic strategy. Moreover, the study will help to define the predictive biomarkers /biosignatures of response to STN DBS in OCD.

03

Conditions studied

  • Obsessive-Compulsive Disorder

Keywords

  • Deep Brain Stimulation
  • Quality of Life
04

Who can participate

Ages eligible
18 Years to 69 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • OCD for > 5 years
  • YBOCS> 25 and/or YBOCS sub-scale >15
  • GAF\< 45
  • 3 or more documented SRI trials, including clomipramine (10-12 weeks at adequate dose)
  • SRI augmentation for > 4 weeks with at least one antipsychotic and with one of the following: lithium, clonazepam
  • Adequate trial of CBT (Exposure Therapy and Response Prevention) (intolerance or >15 sessions)
  • Ability to provide

Exclusion criteria

Exclusion Criteria:

  • Hoarding (if the only OCD symptom)
  • OCD with poor insight (BABS score > 12)
  • Lifetime diagnosis of psychosis or bipolar disorder;
  • Substance abuse or dependence within the previous six months;
  • Baseline Montgomery and Asberg (MADRS) suicidality item (item 10) score >2;
  • Current personality disorder of Cluster A (e.g., paranoid or schizotypal personality disorder) or B (e.g., borderline or antisocial personality disorder);
  • Brain pathology, such as moderate or marked cerebral atrophy, stroke, tumor or previous neurosurgical procedures (i.e. capsulotomy etc), history of cognitive impairment and cognitive deterioration (Addenbrooke's Cognitive Examination ACE score of \< 80).
  • to surgery, anaesthesia, or MRI
  • compulsory hospitalization/ care; pregnant or nursing patients
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
60 participants (estimated)

Study arms

  • Active comparator
    Deep Brain Stimulation

    DBS surgical procedure scheduled and realized

    Device: Deep Brain Stimulation

  • No intervention
    Control group

    medical treatment (psycho- and pharmaco-therapy) will continue to be given and optimized according to the defined BMT strategies and criteria

Interventions

  • DeviceDeep Brain Stimulation

    surgical procedure

    Also known as: DBS

06

What researchers measure

Primary outcomes

  1. Assessment of the impact of DBS+BMT versus BMT alone on a measure of Quality of life in resistant OCD patients at 1-year follow-up

    QOL assessment : scores at SF36

    Time frame: 1 year

Secondary outcomes

  1. Psychiatric assessment n°1

    clinical profile defined by score at YBOCS -Yale Brown Obsessive Compulsive Scale

    Time frame: 1 year

  2. Psychiatric assessment n°2

    clinical profile defined by score at DYBOCS- Dimensional Yale Brown Obsessive Compulsive Scale

    Time frame: 1 year

  3. Psychiatric assessment n°3

    clinical profile defined by score at YMRS (Young Mania Rating Scale)

    Time frame: 1 year

  4. Psychiatric assessment n°4

    clinical profile defined by score at HAMA (Hamilton Rating Scale for Anxiety)

    Time frame: 1 year

  5. Psychiatric assessment n°5

    clinical profile defined by score at STAI (State-Trait Anxiety Inventory)

    Time frame: 1 year

  6. Psychiatric assessment n°6

    clinical profile defined by score at UPPS-P Impulsive Behavior Scale

    Time frame: 1 year

  7. Psychiatric assessment n°7

    clinical profile defined by score at Clinical Global Impression (Severity of OCD)

    Time frame: 1 year

  8. Assessment of the impact of DBS+BMT versus BMT alone on a measure of Functioning score n°1

    Functioning scores : GAF (Global assessment functioning scale)

    Time frame: 1 year

  9. Assessment of the impact of DBS+BMT versus BMT alone on a measure of Functioning score n°2

    Functioning scores : WHODAS 2.0

    Time frame: 1 year

  10. side effects

    Number of patients with side effects related to medical treatment, surgery and to stimulation

    Time frame: 1 year

  11. Psychiatric markers n°1

    scores at Big Five Inventory

    Time frame: 1 year

  12. Psychiatric markers n°2

    scores at BABS (BROWN ASSESSMENT OF BELIEFS SCALE)

    Time frame: 1 year

  13. Neurological markers n°3

    score at UPDRS (Unified Parkinson's Disease Rating Scale)

    Time frame: 1 year

  14. Neuropsychological markers n°4

    Score at OBQ-44 (Obsessive Beliefs Questionnaire)

    Time frame: 1 year

  15. Neuropsychological markers n°5

    Score at MCQ (Metacognitions questionnaires)

    Time frame: 1 year

  16. Neuropsychological markers n°6

    Score at URICA (University Rhode Island Change Assessment Scale)

    Time frame: 1 year

  17. Neuropsychological markers

    Score at Addenbrooke Cognitive Examination (ACE) battery

    Time frame: 1 year

  18. Per-op electrophysiological mapping of the STN activity n°1

    electrophysiological parameters at rest and during OCD provocative tests

    Time frame: 1 year

  19. Per-op electrophysiological mapping of the STN activity n°2

    electrophysiological parameters at rest and during OCD uncertainty test

    Time frame: 1 year

  20. Per-op electrophysiological mapping of the STN activity n°3

    electrophysiological parameters at rest and during OCD emotional test

    Time frame: 1 year

  21. Per-op electrophysiological mapping of the STN activity n°4

    electrophysiological parameters at rest and during OCD cognitive and motor test

    Time frame: 1 year

  22. Assessment of the suicidal risk under DBS+BMT vs BMT in resistant OCD

    Measure of suicidal risk with MADRS scale

    Time frame: 1 year

07

Study locations

7 of 8 sites recruiting
08

References and documents

Publications

  • Subramaniam M, Soh P, Vaingankar JA, Picco L, Chong SA. Quality of life in obsessive-compulsive disorder: impact of the disorder and of treatment. CNS Drugs. 2013 May;27(5):367-83. doi: 10.1007/s40263-013-0056-z. PubMed 23580175 ↗
  • Mallet L, Polosan M, Jaafari N, Baup N, Welter ML, Fontaine D, du Montcel ST, Yelnik J, Chereau I, Arbus C, Raoul S, Aouizerate B, Damier P, Chabardes S, Czernecki V, Ardouin C, Krebs MO, Bardinet E, Chaynes P, Burbaud P, Cornu P, Derost P, Bougerol T, Bataille B, Mattei V, Dormont D, Devaux B, Verin M, Houeto JL, Pollak P, Benabid AL, Agid Y, Krack P, Millet B, Pelissolo A; STOC Study Group. Subthalamic nucleus stimulation in severe obsessive-compulsive disorder. N Engl J Med. 2008 Nov 13;359(20):2121-34. doi: 10.1056/NEJMoa0708514. Erratum In: N Engl J Med. 2009 Sep 3;361(10):1027. PubMed 19005196 ↗
  • Kohl S, Schonherr DM, Luigjes J, Denys D, Mueller UJ, Lenartz D, Visser-Vandewalle V, Kuhn J. Deep brain stimulation for treatment-refractory obsessive compulsive disorder: a systematic review. BMC Psychiatry. 2014 Aug 2;14:214. doi: 10.1186/s12888-014-0214-y. PubMed 25085317 ↗
  • Eitan R, Shamir RR, Linetsky E, Rosenbluh O, Moshel S, Ben-Hur T, Bergman H, Israel Z. Asymmetric right/left encoding of emotions in the human subthalamic nucleus. Front Syst Neurosci. 2013 Oct 29;7:69. doi: 10.3389/fnsys.2013.00069. eCollection 2013. PubMed 24194703 ↗
  • Mataix-Cols D, Fernandez de la Cruz L, Nordsletten AE, Lenhard F, Isomura K, Simpson HB. Towards an international expert consensus for defining treatment response, remission, recovery and relapse in obsessive-compulsive disorder. World Psychiatry. 2016 Feb;15(1):80-1. doi: 10.1002/wps.20299. No abstract available. PubMed 26833615 ↗
  • Piallat B, Polosan M, Fraix V, Goetz L, David O, Fenoy A, Torres N, Quesada JL, Seigneuret E, Pollak P, Krack P, Bougerol T, Benabid AL, Chabardes S. Subthalamic neuronal firing in obsessive-compulsive disorder and Parkinson disease. Ann Neurol. 2011 May;69(5):793-802. doi: 10.1002/ana.22222. Epub 2010 Dec 28. PubMed 21520240 ↗
  • Ooms P, Mantione M, Figee M, Schuurman PR, van den Munckhof P, Denys D. Deep brain stimulation for obsessive-compulsive disorders: long-term analysis of quality of life. J Neurol Neurosurg Psychiatry. 2014 Feb;85(2):153-8. doi: 10.1136/jnnp-2012-302550. Epub 2013 May 28. PubMed 23715912 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Sep 2016 (actual). Primary completion is estimated for Jul 2026, 118 months after the start.

Of 235 non-industry interventional studies with no phase under Obsessive-Compulsive Disorder, half reached primary completion within 43 months of starting (the median), counting those still running; a quarter within 22 and three quarters within 63. This study's planned 118 months is above that.

Counting every sponsor, half of 238 studies reached it within 43 months; a quarter within 22 and three quarters within 63.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 15, 2016
First posted
Jul 26, 2016
StartActual
Sep 2016
Primary completionEst.
Jul 2026
CompletionEst.
Apr 2027
Last update
Nov 29, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 29, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02844049
Responsible party
Sponsor
First posted
Jul 26, 2016
Start date
Sep 2016
Primary completion
Jul 2026 (estimated)
Completion
Apr 2027 (estimated)
Last update
Nov 29, 2023

Study contacts

Sandra David-tchouda, MD
Contact
SDavidTchouda@chugrenoble.fr
+33476767186
Sandrine Massicot, Master
Contact
smassicot@chu-grenoble.fr
+33476768860
Mircea Polosan, MD PhD
principal investigator · University Hospital, Grenoble

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion